Supplementary Material

Supplementary Table T1

FORWARD REVERSE


mTBP hTRP mGLUT1 mGLUT4 mHK mG6PDH mRiboRed mFAS **hFAS** mFAT/CD36 mFABPpm mFATP1 mFATP3 mFATP4 mFATP6 mLPL mDGAT mtGPAT mACS hACS mLXR alpha nLXR alpha mLXR beta mRXR alpha hRXR alpha mRXR beta hRXR beta mRXR gamma mSREBP1c mLipin hGLUT4 hHK hG6PDH


ATATAATCCCAAGCGATTTGC **GCCATAAGGCATCATTGGAC** CGAGGGACAGCCGATGTG GATGAGAAACGGAAGTTGGAGAGA CCCTGCCACCAGACGAAA AGGTGACCCTAAGCCGGAC CTGCTCAGATCACCATGAAAGT CGGAAACTTCAGGAAATGTCC TGTGGACATGGTCACGGAC TGGCCTTACTTGGGATTGG AGCGGCTGACCAAGGAGTT **GGCTCCTGGAGCAGGAACA** CAGCTCTACAGCCATGTTTCTGA GGCTTCCCTGGTGTACTATGGAT **GGCTTGAGGATGCCGCTTA** GGGAGTTTGGCTCCAGAGTTT TCCGTCCAGGGTGGTAGTG ACAGTTGGCACAATAGACGTTT CTCACCATTATATTGCTGCCTGT AAAAGCTAAGCCCACTTCAGAC GGGAGGAGTGTGTGCTGTCAG CATGGCACCAGATCCCCATAG GGCCTGGACGATGCAGAGT AACCCCAGCTCACCAAATGACC TTCGCTAAGCTCTTGCTC GCCAAGCTGCTGTTACGTCTT GAAGCTCAGGAAACACTAC CCGCTGCCAGTACTGTCG GCATGCCATGGGCAAGTAC CTCCGCTCCCGAGAGAAAG CTCAGCAGCGAGTGACTGG GAGCCACCACTCACCCTACT CAAACAGAGTGAGCCCTTCTTC

GTCCGTGGCTCTCTTATTCTC **AACAACAGCCTGCCACCTTA** TGCCGACCCTCTTCTTTCAT **GCACCACTGCGATGATCAGA** GACTTGAACCCCTTAGTCCATGA AGGTTTCTTTGGGTAGAAGACCA TGCTTCGTGGTCAAGGTCG TCAGAGACGTGTCACTCCTGG GGCATCAAACCTAGACAGGTC CCAGTGTATATGTAGGCTCATCCA GACCCCTGCCACGGAGAT ACGGAAGTCCCAGAAACCAA CAAAGATTCCTGGAGCCTGAGA ACGATGTTTCCTGCTGAGTGGTA GTACTCTGGGCTCATGCTATGAAGT **TGTGTCTTCAGGGGTCCTTAG** TGAACAAAGAATCTTGCAGACGA CCTTCCATTTCAGTGTTGCAGA TCTCTTTGCCATAGCGTTTTTCT **ACTTGGATACAGCATGGTCAAAT** GAGCGCCTGTTACACTGTTGC **GGGTAGCTGTTTAGCAAAGTCAA** CGATCGGCTGAGAAGATGTTG **AACAGGACAATGGCTCGCAGG** ATAAGGAAGGTGTCAATGGG ACAGGTGCTCCAGACACTTGAG TGCAGTCTTTGTTGTCCC ACCTGGTCCTCCAAGGTGAG CCACATAGATCTCTGCCAGTGTTG **TCATGTGCAAATCCACGGACT** CCCCAATGTTGTACCCAAACTG ACCCAAAGCACACGGAAGTT CTCATGCAGGACTCGTGAATG

Supplementary Table T1


Sequences of primers used for RT-PCR. m, mouse-specific primers; h, human-specific primers.






Supplementary Figure S1. Incorporation of de-novo synthesized lipids into different lipid components.

(A and B) Tritium labeled free fatty acids (A) and triglycerides (B) in glycolytic muscle of MPGC-1 α TG mice vs. controls. All values are means \pm SE. (n=5 per group). ** p<0.01.




Supplementary Figure S2. Enhanced lipid anabolism in isolated muscle cells overexpressing PGC-1\alpha.

(A-C) FAS gene expression (A), activity (B) and *de-novo* lipogenesis (C) in isolated muscle cells overexpressing either GFP (control), or PGC-1 α . All values are means \pm SE. (n=8 per group). * p<0.05; ** p<0.01.




Supplementary Figure S3. Lipin gene expressionRelative gene expression of lipin in EDL as measured by RT-PCR and expressed as fold change over controls.




Supplementary Figure S4. Luciferase assay

Promoter activity of the FAS wild-type promoter (FAS-wt) and of a SREBP_binding mutant (FAS-mutant) following transfection of myoblasts with pcDNA (empty vector) (black bars) or PGC-l α (grey bars). LXR α /RXR α expression plasmids were cotransfected for all assays. Values are expressed as means \pm SE (n =6 per group)



Supplementary Figure S5. Increased Glucose-6-phosphate levels in muscle and elevated G6PDH activity in isolated muscle cells overexpressing PGC-1α.

- (A) Glucose-6-phosphate (G6P) levels in glycolytic muscles of MPGC-1 α TG mice vs. controls. All values are means \pm SE. (n=5-6 per group). * p<0.05.
- (B) G6PDH activity in isolated muscle cells overexpressing either GFP (control), or PGC-1 α . All values are means \pm SE. (n=6 per group). * p<0.05.



Supplementary Figure S6. GLUT4, HK2 and G6PDH mRNA levels in endurance athletes preand post-exercise.

(A-C) Relative expression of GLUT4 (A), HK2 (B) and G6PDH (C) in human muscle biopsies preand post-exercise. Mean values are expressed as bars with SE (n=6). * p<0.05 as assessed by paired t-test.